The fibrinogen–albumin ratio (FAR) is a novel inflammatory and nutritional biomarker that has demonstrated prognostic efficiency across diverse cancers, including esophageal cancer [21], hepatocellular carcinoma [22], osteosarcoma [23], non-small-cell lung cancer [24], and ovarian cancer [25]. Here, ALB is linked to cancer.